EP4482821A4 - APOPTOSE-RELATED PROTEIN IN MAMETIC LINKS OF THE TGF-BETA SIGNAL PATHWAY (ARTS), COMPOSITIONS, METHODS AND USES THEREOF IN THE INDUCTION OF APOPTOSE - Google Patents

APOPTOSE-RELATED PROTEIN IN MAMETIC LINKS OF THE TGF-BETA SIGNAL PATHWAY (ARTS), COMPOSITIONS, METHODS AND USES THEREOF IN THE INDUCTION OF APOPTOSE

Info

Publication number
EP4482821A4
EP4482821A4 EP23759470.0A EP23759470A EP4482821A4 EP 4482821 A4 EP4482821 A4 EP 4482821A4 EP 23759470 A EP23759470 A EP 23759470A EP 4482821 A4 EP4482821 A4 EP 4482821A4
Authority
EP
European Patent Office
Prior art keywords
apoptose
mametic
tgf
arts
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23759470.0A
Other languages
German (de)
French (fr)
Other versions
EP4482821A1 (en
Inventor
Sarit Larisch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carmel Haifa University Economic Corp Ltd
Original Assignee
Carmel Haifa University Economic Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carmel Haifa University Economic Corp Ltd filed Critical Carmel Haifa University Economic Corp Ltd
Publication of EP4482821A1 publication Critical patent/EP4482821A1/en
Publication of EP4482821A4 publication Critical patent/EP4482821A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP23759470.0A 2022-02-25 2023-02-24 APOPTOSE-RELATED PROTEIN IN MAMETIC LINKS OF THE TGF-BETA SIGNAL PATHWAY (ARTS), COMPOSITIONS, METHODS AND USES THEREOF IN THE INDUCTION OF APOPTOSE Pending EP4482821A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263313789P 2022-02-25 2022-02-25
PCT/IL2023/050198 WO2023161940A1 (en) 2022-02-25 2023-02-24 Apoptosis related protein in the tgf-beta signaling pathway (arts) mimetic compounds, compositions, methods and uses thereof in induction of apoptosis

Publications (2)

Publication Number Publication Date
EP4482821A1 EP4482821A1 (en) 2025-01-01
EP4482821A4 true EP4482821A4 (en) 2026-02-18

Family

ID=87765063

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23759470.0A Pending EP4482821A4 (en) 2022-02-25 2023-02-24 APOPTOSE-RELATED PROTEIN IN MAMETIC LINKS OF THE TGF-BETA SIGNAL PATHWAY (ARTS), COMPOSITIONS, METHODS AND USES THEREOF IN THE INDUCTION OF APOPTOSE

Country Status (3)

Country Link
EP (1) EP4482821A4 (en)
IL (1) IL315185A (en)
WO (1) WO2023161940A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001666A1 (en) * 1998-07-02 2000-01-13 Idun Pharmaceuticals, Inc. C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES
WO2013192274A2 (en) * 2012-06-19 2013-12-27 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
WO2023166507A1 (en) * 2022-03-01 2023-09-07 Carmel-Haifa University Economic Corporation Ltd. Apoptosis related protein in the tgf-beta signaling pathway (arts) and arts mimetic small molecule compounds for upregulating p53 level
WO2023175615A1 (en) * 2022-03-14 2023-09-21 Carmel-Haifa University Economic Corporation Ltd. Arts mimetic componds and combinations thereof for treating high-risk neuroblastoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015035051A1 (en) * 2013-09-04 2015-03-12 Board Of Regents Of The University Of Texas System Methods and compositions for selective and targeted cancer therapy
EP3426674A4 (en) * 2016-03-09 2019-08-14 Blade Therapeutics, Inc. CYCLIC CE-AMIDE COMPOUNDS AS MODULATORS OF CALPAIN, AND METHODS OF MAKING AND USING SAME

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001666A1 (en) * 1998-07-02 2000-01-13 Idun Pharmaceuticals, Inc. C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES
WO2013192274A2 (en) * 2012-06-19 2013-12-27 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
WO2023166507A1 (en) * 2022-03-01 2023-09-07 Carmel-Haifa University Economic Corporation Ltd. Apoptosis related protein in the tgf-beta signaling pathway (arts) and arts mimetic small molecule compounds for upregulating p53 level
WO2023175615A1 (en) * 2022-03-14 2023-09-21 Carmel-Haifa University Economic Corporation Ltd. Arts mimetic componds and combinations thereof for treating high-risk neuroblastoma

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABDEL-ALIM A M ET AL: "Synthesis and pharmacological evaluation of some novel oxanilamides", ARCHIV FOR PHARMACI OG CHEMI, SCIENTIFIC EDITION, vol. 12, no. 1, 1 January 1984 (1984-01-01), pages 8 - 16, XP093351854 *
CLAVIER H ET AL: "Design and synthesis of new bidentate alkoxy-NHC ligands for enantioselective copper-catalyzed conjugate addition", JOURNAL OF ORGANOMETALLIC CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 690, no. 23, 15 November 2005 (2005-11-15), pages 5237 - 5254, XP027708760, ISSN: 0022-328X, [retrieved on 20051115] *
DATABASE REGISTRY [online] Chemical Abstract Service, Columbus, Ohio, US; 16 October 2023 (2023-10-16), XP093351723, retrieved from https://stn.org/stn/# Database accession no. 2989484-76-4 *
DATABASE REGISTRY [online] Chemical Abstract Service, Columbus, Ohio, US; 23 December 2011 (2011-12-23), XP093351713, retrieved from https://stn.org/stn/# Database accession no. 1351769-21-5 *
See also references of WO2023161940A1 *
STRAND RAGNHILD B ET AL: "Synthesis of amino acid derived imidazolidinium salts as new NHC precatalysts", TETRAHEDRON ASYMMETRY, vol. 22, no. 23, 1984, pages 1994 - 2006, XP028886420, ISSN: 0957-4166, DOI: 10.1016/J.TETASY.2011.11.015 *

Also Published As

Publication number Publication date
IL315185A (en) 2024-10-01
EP4482821A1 (en) 2025-01-01
WO2023161940A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
MX2022005357A (en) RAS INHIBITORS.
IL284223A (en) Alternative configurations of 3-((3-aminophenyl)amino)piperidine-2,6-dione - materials, compositions and methods of treatment
MX2024004247A (en) RAS INHIBITORS.
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
ATE515277T1 (en) COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS
TR200102030T2 (en) pharmaceutical composition including on
DK0686151T3 (en) Substituted cyclic carbonyl compounds and derivatives thereof which can be used as retroviral protease inhibitors
CY1109784T1 (en) Substituted glutarimides and their use as IL-12 inhibitors
EP4422623A4 (en) PROLYLHYDROXYLASE DOMAINE-CONTAINING PROTEIN (PHD) Inhibitors and Uses Thereof
DE602005027580D1 (en) INHIBITORS OF THE RNA-DEPENDENT RNA POLYMERASE OF HEPATITIS C VIRUS AND COMPOSITIONS AND TREATMENTS THEREOF WHERE THEY ARE USED
NO20064547L (en) Methods for treating HIV infection
MX2021004580A (en) 5-membered heteroaryl carboxamide compounds for treatment of hbv.
IL284187A (en) Alternative configurations of 3-((3-aminophenyl)amino)piperidine-2,6-dione - materials, compositions and methods of treatment
NO20080797L (en) Bicyclic heterocycles such as HIV Integrase inhibitors
EP1603391A4 (en) METHOD OF USE OF COMPOSITIONS COMPRISING HIGH SHOCK PROTEINS OR ALPHA-2-MACROGLOBULIN IN THE TREATMENT OF CANCER AND INFECTION DISEASES
EP4486722A4 (en) COMPOSITIONS, COMPOSITIONS AND PROCEDURES
BR112022018480A2 (en) NLRP3 MODULATORS
ATE349448T1 (en) PYRAZOLE-3,4-D-PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF H.PYLORI INFECTIONS
DE60230456D1 (en) FACTOR VIII POLYPEPTIDES AT HIGH EXPRESSION LEVEL AND METHOD OF USE
EP4640282A3 (en) Immunodominant proteins and fragments in multiple sclerosis
EP4482821A4 (en) APOPTOSE-RELATED PROTEIN IN MAMETIC LINKS OF THE TGF-BETA SIGNAL PATHWAY (ARTS), COMPOSITIONS, METHODS AND USES THEREOF IN THE INDUCTION OF APOPTOSE
ATE359816T1 (en) METHOD FOR PREVENTING AND TREATING FLAVIVIRUS INFECTIONS IN ANIMALS
EP4337174A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
EP4352240A4 (en) Polynucleotide compositions, associated formulations and methods of using the same
EP4499626A4 (en) COMPOSITIONS, COMPOSITIONS AND PROCEDURES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07C0233560000

Ipc: A61K0031416400

A4 Supplementary search report drawn up and despatched

Effective date: 20260121

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4164 20060101AFI20260115BHEP

Ipc: C07C 233/56 20060101ALI20260115BHEP

Ipc: A61K 31/16 20060101ALI20260115BHEP

Ipc: C07D 233/64 20060101ALI20260115BHEP

Ipc: A61K 31/4184 20060101ALI20260115BHEP

Ipc: A61K 31/635 20060101ALI20260115BHEP

Ipc: A61K 45/06 20060101ALI20260115BHEP

Ipc: A61P 35/00 20060101ALI20260115BHEP